IntuitionLabs
GxP validation and 21 CFR Part 11 compliance services for Sapio Sciences in pharma and biotech

GxP Validation & 21 CFR Part 11 Compliance for Sapio Sciences

Risk-based validation aligned with GAMP 5, FDA Computer Software Assurance, and EU Annex 11. URS through PQ, periodic review, inspection-ready evidence — for Sapio LIMS, ELN, and Jarvis SDMS in pharma, biotech, and CRO environments.

Our Sapio Validation Services

Three packaged service tracks covering new validations, re-validations, and ongoing compliance — all aligned with GAMP 5 Second Edition and FDA Computer Software Assurance principles.

New Deployments
Initial Validation
Full URS-through-PQ validation for new Sapio deployments across LIMS, ELN, and Jarvis SDMS modules. Risk-based, CSA-aligned, with automated regression test packs that pay back on every future change.
Plan validation
Existing Systems
Re-Validation & Remediation
Bring legacy or under-validated Sapio deployments up to current GAMP 5 and 21 CFR Part 11 expectations — including 483 and warning letter remediation programmes.
Discuss remediation
Ongoing
Periodic Review & Managed Compliance
Annual periodic review, change control review, integration regression testing, and inspection support delivered as a fixed-fee retainer or embedded resource model.
Managed compliance

Aligned with GAMP 5 Second Edition

Every validation deliverable maps cleanly to ISPE GAMP 5 Second Edition — the recognised framework for computerised systems in regulated life sciences. We document the categorisation decision per component (Category 4 for configuration, Category 5 for bespoke), scope validation effort accordingly, and revisit on every change. The output is proportionate validation — heavy where risk is high, light where it isn't — instead of the boilerplate over-validation that plagues legacy programmes.

GAMP 5 Second Edition validation framework applied to Sapio Sciences for pharma and biotech

Built for FDA, EMA, and MHRA Inspection

The validation evidence pack is structured to mirror the questions inspectors actually ask. We integrate the latest FDA expectations from recent data integrity warning letters, EU Annex 11, and MHRA data integrity guidance so the narrative aligns with what inspectors care about right now, not what was current ten years ago.

Inspection-ready validation evidence for Sapio Sciences covering FDA, EMA, and MHRA expectations

Risk-Based, CSA-Aligned Testing

FDA's Computer Software Assurance draft guidance shifts validation from documentation volume to critical thinking and risk-based assurance. We use unscripted testing for low-risk features, scripted testing for high-risk GxP-impacting functionality, and automated regression for everything that should be machine-checked. CSA fits Sapio's no-code platform especially well — light validation for small configuration changes, deep testing for high-impact workflows.

Risk-based Computer Software Assurance approach to validating Sapio Sciences with automated regression testing

What Validation Looks Like in Practice

Six core deliverables that make up a complete Sapio validation package — adjusted for scope and risk, not photocopied between projects.

Validation Plan & Risk Assessment

Top-of-stack document defining scope, methodology, GAMP 5 categorisation per component, and the risk register that drives test depth. Approved by Quality before any other artefact is finalised.

Discuss planning

URS, FRS, and Configuration Specs

Traceable specification chain — User Requirements through Functional and Configuration Specifications — so every test in OQ and PQ traces back to a regulated requirement and forward to evidence.

Discuss specs

IQ / OQ / PQ Protocols

Risk-based protocols leveraging Sapio-supplied documentation where possible. Automated regression test packs cover the protocols that are run repeatedly across releases — a one-time investment that compounds on every future change.

Discuss protocols

Traceability Matrix

Single source of truth linking URS items to specifications, test cases, executed evidence, and defects. Inspectors ask for it on day one of every meaningful audit; ours is generated and maintained from the test management tool, not hand-typed.

Discuss traceability

SOPs & Periodic Review

SOPs covering audit trail review, user access management, change control, backup and restore verification, and incident response. Periodic review template aligned with GAMP 5 and ICH Q9(R1) quality risk management.

Discuss SOPs

Validation Summary Report

Final sign-off document tying together every artefact, deviations, change controls, and outstanding risks accepted by Quality. The single document an inspector reads first to assess validation maturity.

Discuss VSR

Why IntuitionLabs for Validation

Validation done by people who also build the system is dramatically more efficient than validation done by people who only write paper. We do both, on the same project, with the same team.

Combined Eng + QA

Same team configures, integrates, validates, and supports — no handoff drift between implementation and validation deliverables.

CSA Native

Risk-based, leaner validation aligned with FDA CSA and GAMP 5 Second Edition. Inspection-defensible without boilerplate over-validation.

AI Validation Capable

We validate ELaiN and other AI integrations on Sapio with the same rigour as classic functionality — not as an unmanaged shadow IT layer.

Regulatory Frameworks We Cover

🇺🇸

21 CFR Part 11

Full Subpart B and C coverage — electronic record controls, audit trail requirements, electronic signature manifestations, and signature/record linking — explicitly mapped against Sapio configuration and procedural controls.

🇪🇺

EU Annex 11

Risk management, supplier audit, validation, data, accuracy checks, data storage, audit trails, change and configuration management, business continuity, and electronic signature — addressed in a single integrated dossier alongside Part 11.

📚

GAMP 5 Second Edition

Categorisation, lifecycle, risk-based validation, supplier leveraging, and critical thinking applied per ISPE Second Edition guidance. The default operating model for every Sapio engagement we run.

🛡️

MHRA & WHO Data Integrity

ALCOA+ data integrity addressed at the technical and procedural level. Audit trail isolation, time-zone neutrality, immutable versioning, and dual-control review baked into the validation evidence pack.

🌐

ICH Q8 / Q9 / Q10 / Q11

Pharmaceutical development, quality risk management, pharmaceutical quality system, and drug substance development guidance applied to PD, QC, and analytical workflows running on Sapio.

✅

FDA Computer Software Assurance

CSA principles applied throughout — unscripted testing for low-risk features, scripted testing for high-risk GxP functionality, automated regression for repeatability, and proportionate documentation that satisfies inspectors without consuming excess time.

Frequently Asked Questions

A complete validation deliverable for the Sapio Sciences platform covers the full lifecycle defined in ISPE GAMP 5 Second Edition: validation planning and risk assessment, User Requirements Specification (URS), Functional and Configuration Specifications, design qualification, Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), traceability matrix, validation summary report, SOPs, periodic review framework, and change control procedures. The depth of each artefact is risk-based, aligned with FDA Computer Software Assurance principles — heavy testing on functions that affect product quality or patient safety, lighter on low-risk configuration. Because Sapio unifies LIMS, ELN, and SDMS, the validation dossier covers all three modules in one defensible package rather than three parallel exercises.
We produce an explicit 21 CFR Part 11 mapping that walks through Subpart B (Electronic Records, §11.10 controls for closed systems and §11.30 for open systems) and Subpart C (Electronic Signatures, §11.50 signature manifestations and §11.70 signature/record linking) line by line, identifying for each requirement: how Sapio addresses it, what configuration choices are required, and what procedural controls the customer must implement. The same mapping is repeated against EU Annex 11 and WHO TRS 996 Annex 5. The result is a single defensible compliance dossier rather than three parallel exercises.
Sapio is configured rather than coded for the vast majority of customer use cases — its no-code app builder is one of its core selling points — which places the platform in GAMP 5 Category 4 (configured products). Where customers add custom plugins, scripted analyses, or bespoke ELaiN extensions, those elements move into Category 5 (custom applications) and require correspondingly deeper validation. We document the categorisation decision per component, scope validation effort accordingly, and revisit on every change. This is how we keep validation effort proportionate to actual risk rather than blanket over-validating low-risk configuration.
For a focused single-site, single-business-unit deployment with a defined scope (for example, a clinical NGS lab or a QC laboratory), validation completes in 8-14 weeks. For a multi-site enterprise deployment with multiple integrations, bespoke ELaiN configurations, and CGT-specific workflows, plan for 5-9 months running in parallel with implementation. The risk-based approach — and intelligent reuse of Sapio-supplied IQ/OQ documentation — is what compresses these timelines compared to traditional validation. We also push as much testing as possible into automated regression suites that pay back on every future Sapio release.
Data integrity validation focuses on the ALCOA+ principles described in MHRA GxP Data Integrity Guidance: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available. We test the technical controls (audit trail capture, time-stamp accuracy and time-zone neutrality, immutable versioning, audit trail isolation from administrator modification) and the procedural controls (audit trail review SOPs, dual-control approval, password and access reviews). We also test failure modes — for example, what happens if a user attempts to delete a signed record, modify a timestamp, or bypass approval — and document the system response with reproducible evidence. The same rigour is applied to data flowing into Jarvis from instruments and external sources.
Yes — FDA's Computer Software Assurance (CSA) draft guidance is the operating model we recommend for new validations and re-validations. CSA shifts emphasis from documentation volume to critical thinking, risk-based assurance activities, and unscripted testing for low-risk features — directly aligned with GAMP 5 Second Edition. The result is a leaner validation deliverable that satisfies inspectors while consuming much less internal time. CSA fits naturally with Sapio's no-code app builder — small low-risk configuration changes can move through validation lightly, while high-risk GxP-impacting workflows still receive full scripted testing.
Integrations are validated as system components in their own right. For each interface we produce: an interface specification (what data, in what format, in which direction, with what error handling), a risk assessment, test cases covering happy path, edge cases, and failure modes (including network partition and partial-write scenarios), and a reconciliation strategy for periodic verification of data flows. ALCOA+ traceability follows the data across the boundary — for example, a sequencing result entering Sapio from an Illumina instrument retains the original instrument file reference, operator, timestamp, and run metadata. This satisfies MHRA expectations for end-to-end data integrity.
Sapio is delivered as a cloud platform, which changes the validation pattern but not the obligation. We follow the supplier-leveraged validation pattern in GAMP 5 — auditing Sapio's quality management system, leveraging supplier-provided IQ/OQ where available, and focusing customer validation on configuration, business processes, and integrations. Cloud-specific risks (release cadence, multi-tenancy, data location, vendor breach response) are addressed through a supplier audit, contractual SLAs, and a continuous monitoring plan. The principles are documented in ISPE GAMP IT Infrastructure guidance.
Periodic review on a defined cadence (typically annual) checks that the validated state still holds — that change controls have been honoured, security configuration has not drifted, audit trail review SOPs are being executed, and that no new Sapio releases or integration changes have introduced unvalidated behaviour. We provide a periodic review template aligned with GAMP 5 expectations and ICH Q9(R1) quality risk management. Where the review identifies regression risk, we trigger targeted re-qualification rather than full re-validation — keeping cost proportionate to risk.
Inspection-readiness is built in from day one. The validation evidence pack is structured to mirror the questions that inspectors actually ask — the FDA Title 21 inspection guides, EMA EU GMP Annex 11, and MHRA data integrity guidance. We provide inspection-day support: pre-inspection mock interviews with system owners, a controlled binder of evidence indexed to inspector questions, and on-site SME availability during the inspection itself. Recent FDA data integrity warning letters are factored into the evidence narrative so inspectors see we are addressing what they care about now.
Yes — migration validation is a discrete deliverable that demonstrates data integrity is preserved when moving from paper notebooks, Thermo Watson, STARLIMS, LabWare, BIOVIA, LabArchives, or custom systems to Sapio. The protocol covers source-to-target mapping, automated reconciliation (record counts, checksums, referential integrity), trial migration in a qualified staging environment, parallel-run with the legacy system in read-only mode, and a final sign-off pack documenting chain of custody. This evidence is exactly what inspectors expect under FDA data integrity guidance.
AI components — including ELaiN extensions — are validated as configured items aligned with GAMP 5 and the FDA draft guidance on AI in drug development. We version-pin every model and prompt, maintain a regression test pack covering known-good prompts, run a continuous evaluation harness that flags drift on every provider release, and document the human-in-the-loop approval pattern that keeps AI as a drafting aid rather than an unsupervised actor. The evidence pack is integrated with the broader Sapio validation rather than living in a separate AI silo.
Ready to Get Your Sapio Validation Inspection-Ready?
Ready to Get Your Sapio Validation Inspection-Ready? image

Ready to Get Your Sapio Validation Inspection-Ready?

Book a discovery session to scope a risk-based, CSA-aligned validation of your Sapio LIMS, ELN, or Jarvis environment — built to satisfy FDA, EMA, and MHRA inspectors without boilerplate over-validation.

Book a Meeting

© 2026 IntuitionLabs. All rights reserved.

Privacy PolicyTerms of ServiceBook Meeting